Abstract. Genistein has been investigated for several decades for its potential role in breast cancer prevention. Previous researches have shown that glucuronide and sulfate conjugates are the major species circulating in the blood after genistein ingestion. It was hypothesized that enzymes (UDPglucuronosyltransferases, sulphotransferases, β-glucuronidases, and sulphatases) present in breast tissues would catalyze the inter-conversion between the aglycone and the conjugates in situ. Therefore, our aim was to investigate how genistein, genistein-7-glucuronide (G-7-G), genistein-7-sulfate (G-7-S), and 4′-sulfate (G-4′-S) were metabolized in mammary cells and to determine the effects of metabolism on their proliferative actions using cultured breast cell lines. As expected, genistein stimulated the cell growth of breast cancer cells (MCF-7 and T47D) concentration-dependently at lower concentrations but inhibited their growth at higher concentration. It showed low activities in a non-tumorigenic cell line (MCF-10A) due to the absence of ERα. Genistein was extensively metabolized to glucuronides by MCF-7 and to sulfates by T47D, while it was poorly metabolized by MCF-10A. G-7-G displayed weak stimulation activity in breast cancer cells. G-7-G underwent extensive metabolism in T47D and MCF-10A but not in MCF-7. The proliferative effects of G-7-G on MCF-7 and T47D were associated with its hydrolysis to genistein in these cells. In contrast, G-7-S and G-4′-S were not metabolized by these three cells and had no effects on their growth. In conclusion, production of phase II metabolites did not affect the proliferation effect of genistein on MCF-7 and T47D. Deconjugation was correlated to the apparent proliferative effects of G-7-G in breast cancer cells.
INTRODUCTION
Genistein, the principal isoflavone found in soybean, is a plant polyphenolic compound with chemical structure similar to mammalian estrogens. Isoflavones including genistein have been reported to exert purported health benefits in aging-related and hormone-dependent disorders as well as cardiovascular diseases (1, 2) . Isoflavones, especially genistein, are thought to be responsible for the cancer prevention effects of soy and soy products (3) (4) (5) . Proposed anticancer mechanisms of action include modulation of estrogen receptor (ER) signaling as a partial agonist of ERα and β (6), downregulation of protein kinases and DNA topoisomerase (7), induction of early mammary cell differentiation (8) , inhibition of angiogenesis (9) , and modulation of intracellular enzyme activities (10) . However, a few reports have shown that genistein can also increase proliferation of breast cancer cells in vitro and in ovariectomized rodent models of breast cancer (11) (12) (13) (14) , suggesting the effects of genistein on the breast cancer cell growth may be multifaceted.
Genistein is absorbed from intestinal tract. Most of the absorbed genistein circulate in the blood in the form of glucuronides and sulfates due to extensive phase II metabolism in intestine and liver (15, 16) . The plasma concentration of the aglycone (<400 nM) is much less than the IC 50 values (10−50 μM) reported for its anticancer effect in vitro, even after ingestion of large amounts of genistein (5, 17, 18) . Epidemiological studies indicated that a decreased rate of breast cancer is linked to a higher intake of isoflavone and higher overall level of plasma genistein (the total plasma concentration of aglycone+ phase II conjugates) in Asian women (5, 19) . Although the concentrations of conjugates are much higher in vivo, the effects of genistein glucuronides and sulfates on proliferation of breast cells have not been investigated sufficiently. A limited amount of published data suggested that both genistein glucuronides and genistein sulfates have binding ability to ERs. Compared with the unconjugated compound, the sulfates have weaker estrogenic agonist activity; but the glucuronides are more active in activating human natural killer cells (20, 21) .
Investigation of the effects of genistein conjugates on the proliferation of mammary cell should include its metabolism by these cells, since human mammary cells possesses UDP-glucuronosyltransferases (UGTs) and sulphotransferases (SULTs) that biotransform genistein to its conjugates, as well as β-glucuronidases and sulphatases that catalyze the opposite hydrolysis reactions (22) (23) (24) (25) (26) . In essence, when circulating genistein and phase II conjugates are distributed into the breast tissue, they could undergo inter-conversion by these enzymes. Therefore, it is hypothesized that the overall activity of genistein or its conjugates in breast cells will depend on the activities of the aglycone and the intrinsic activities of the conjugates, as well as the activities of the various enzymes that could impact the interconversion. Elucidation of the inter-conversion metabolism of genistein and its conjugates in mammary cells will help us understand their effects on these cells. Two earlier studies have demonstrated the metabolism of genistein in breast cancer cells (27, 28) , but the concentrations of genistein used (3.7 and 26 μM) far exceeded the concentration commonly achieved in human plasma or tissue after soy consumption (17, 18) . Therefore, in the present study, we assessed the effects of genistein and its phase II conjugates on proliferation of breast cells, investigated how they were metabolized in breast cells, and determine if their metabolism have a direct impact on their proliferative activities in mammary cells. Two ER-positive (ER + ) breast cancer cell lines, MCF-7 and T47D, and a non-transformed epithelial cell line derived from human fibrocystic mammary tissue, MCF-10A, were applied in this study.
MATERIALS AND METHODS

Chemicals
Genistein (>98% purity) and daidzein (>98% purity) were supplied by Xi'an Shanchuan Biopharm Co. (Xi'an, China). Genistein-7-sulfate (G-7-S) and 4′-sulfate (G-4′-S) were chemically synthesized, and 7-glucuronide (G-7-G) was isolated from rat urine in our laboratory. Their structures were identified by nuclear magnetic resonance (NMR). Fetal bovine serum, cell culture media (Dulbecco's modified Eagle's medium (DMEM)), supplements, and antibiotics were obtained from Gibco (Grand Island, NY, USA), Hyclone (Logan, UT, USA), or Amresco (Solon, OH, USA). Estradiol (E2), uridine diphosphoglucuronic acid (UDPGA), alamethicin, D-saccharic-1,4-lactone monohydrate, 3′-phospho-adenosine-5′-phosphosulfate (PAPS), and Hanks' balanced salt solution (HBSS, powder form) were purchased from Sigma-Aldrich (St. Louis, MO, USA). High-performance liquid chromatography (HPLC)-grade methanol and acetonitrile were purchased from Yuwang Industrial Co. Ltd. (Shandong, China). Distilled water, prepared from de-mineralized water, was used throughout the study. All other chemicals and solvents were of analytical grade and used without further purification.
Chemical Synthesis of Genistein-7-Sulfate (G-7-S) G-7-S was synthesized as described previously (29) . In brief, genistein (GEN) (1 g, 0.0037 mol) and hexanoyl chloride (0.8 mL) was mixed in DMF (8 mL) for 24 h to form genistin-7-hexanoate. Then genistin-7-hexanoate was purified on silica gel (Qingdao Haiyang Chemical Co. Ltd, Shandong, China) by eluting with ethyl acetate-petroleum ether (5:1, v/v). After chlorosulfonic acid (2% in 10 mL CH 2 Cl 2 ) was slowly added into the purified genistein-7-hexanoate (1.1 g, 0.0013 mol) which was dissolved in pyridine (10 mL) at 0°C, the mixture was reacted at room temperature for 12 h. 
Chemical Synthesis of Genistein-4′-Sulfate (G-4′-S)
G-4′-S was synthesized as described previously (29) . Benzoyl chloride (0.7 mL) was mixed with GEN (1.5 g, 0.0056 mol, in 10 mL pyridine) at room temperature for 24 h. Then genistein-7-benzoate was precipitated from the solution by addition of 5% HCl. After chlorosulfonic acid (7% in 10 mL CH 2 Cl 2 ) was slowly added into genistein-7-benzoate (1.7 g, 0.0045 mol) which was dissolved in pyridine (10 mL) at 0°C, the following operations were then performed in the same way as described in the synthesis of G-7-S. The white precipitant (0.9 g, ≈98%) was identified as G-4′-S by NMR [δ, 6.23 Isolation of Genistein-7-Glucuronide (G-7-G) Twenty female Wistar rats (6−7 weeks old) were supplied by Laboratory Animal Center of Shenyang Pharmaceutical University (Shenyang, China). They were housed under standard conditions and had ad libitum access to water. All experimental procedures were performed in accordance with the guidelines of the Experimental Animal Care and Use Committee of Shenyang Pharmaceutical University (Shenyang, China). To obtain the reference compound of G-7-G, the animals were orally dosed with genistein at 10 mg/kg (body weight, 180−220 g) in 0.1% sodium carboxymethyl cellulose suspension twice daily for 20 days. After dosing, they were housed in individual steel metabolism cages. Urine samples were collected and pooled every 12 h. All the samples were stored at −80°C until use.
Pooled urine samples were filtered by 0.45 μm filter membrane and subjected to purification using Agilent 1100 preparative HPLC. Separation was accomplished on a Kromasil C 18 column (250×20 mm I.D., 15 μm, Phenomenex, Tianjin, China) with the UV detector set at 254 nm. Methanol-water (30: 70, v/v) was used as the mobile phase with a flow rate of 9.0 mL/ min. Fraction containing G-7-G (t R =7.4 min) was collected and evaporated by vacuum distillation at 35°C to remove methanol. The aqueous fraction was lyophilized, and the product was identified as G 
Cell Culture
Human breast cancer cell lines MCF-7 and T47D, and non-tumorigenic cell line MCF-10A were obtained from American Type Culture Collection (Rockville, MD, USA). All the cells were routinely cultured in DMEM supplemented with 10% fetal bovine serum (FBS), penicillin (100 IU/mL), and streptomycin (100 mg/mL) at 37°C in an atmosphere of 5% CO 2 /95% air under saturating humidity. They were maintained as monolayers in 25 cm 2 flasks and passed once a week. The cells were passed for a maximal of eight times after their use was initiated to maintain consistency.
RNA Extraction and RT-PCR
RT-PCR was performed as described previously (31) , which was used to semi-quantitatively determine the levels of mRNA in genes of the interest. An RNeasy Mini kit was used to extract total RNA (Qiagen, Hilden, Germany), and the RT-PCR kit was from TAKARA Biotechnology Corporation (Dalian, China). Human actin, beta (ACTB), mRNA was used as a control. The primers used for RT-PCR were designed by Primer 3 (v. 0.4.0) software and synthesized by Beijing Sunbiotech Co., Ltd. (Beijing, China). Primer sequences were as follows: human estrogen receptor 1 (ERα) (ESR1), sense 5′-AACGCGCA GGTCTACGGTCA-3′, antisense 5′-TGGTG-CACTGG TTGGTGGCTGCTTCT-30, 481 bp; human estrogen receptor 2 (ERβ) (ESR2), sense, 5′-TGCCGGCAAGGCCAAGA GAA-3′, antisense 5′-AGCATCGGTCACGGCGTTCA-3′, 586 bp; ACTB, sense, 5′-AGAGATGGCCACGGCTGCTT-3′, antisense 5′-GGCAAGGGACTTCCTGTAACAACG-3′, 743 bp.
Cell Proliferation Assay
Cells were seeded in 96-well plates (MCF-7, 2,000 cells/ well; T47D and MCF-10A, 4,000 cells/well) in phenol-red free DMEM containing with 10% dextran-charcoal-stripped FBS for 3 days with one medium change on day 2. On day 4, medium with test compounds was added, and incubation was continued until day 7. The tested concentrations were 0.1, 1.0, 10, 100 pM, 1.0, 10, and 100 nM for E2; 5. 5 cells/well) for 4 days to achieve 80% confluence. After the cells were washed three times with 37°C pH 7.4 HBSS, they were incubated with genistein (100 nM, 1 μM, and 10 μM), G-7-S (1 μM), G-4′-S (1 μM), or G-7-G (1 μM) at 37°C for 1, 2, 4, and 24 h. Then, 300 μL of incubation sample was collected and spiked with 100 μL of internal standard (10 μM daidzein in acetonitrile). The mixture was vortexed for 1 min and centrifuged at 16,700×g for 15 min. Supernatant was applied to ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) analysis. The concentrations of the tested compounds were chosen according to the IC 50 values in vitro and their plasma concentrations in vivo (18, 27, 28) . All the compounds were dissolved in DMSO-ethanol (1: 4, v/v), and the final solvent concentration in incubation medium (HBSS, pH 7.4) was 0.1%. After incubation, the protein concentration of cells in each well was determined by Coomassie brilliant blue colorimetric method to correct for the effect of cell numbers on enzyme activity. Every experiment was performed in triplicate. Controls were prepared the same way except that there were no cells. Blank samples were assayed without the tested compounds to exclude analytical interference by the matrix.
Mammary Cell Lysates
Human mammary cell monolayers were collected into prealiquoted 100 mM Tris-HCl buffer (pH 7.4) and sonicated for 20 min in an ice-cold water bath. The resulting cell lysate was then harvested and used freshly in the experiments. The protein concentration of cell lysate was determined by Coomassie brilliant blue colorimetric method.
Measurement of UGT Activities Using Cell Lysate
Genistein (100 nM, 1 μM or 10 μM) was mixed with breast cell lysate (the final protein concentration was 300 μg/ mL), magnesium chloride (0.88 mM), saccharolactone (4.4 mM), and alamethicin (0.022 mg/mL) in 100 mM TrisHCl buffer (pH 7.4). A solution of 3.5 mM UDPGA was added to start the reaction, which contained a total volume of 300 μL. After incubating at 37°C for 4 h, the reaction was stopped by the addition of 100 μL of internal standard (10 μM daidzein in acetonitrile). Supernatant was separated by centrifugation at 16,700×g for 15 min and then used in UPLC-MS/MS analysis.
Measurement of SULT Activities Using Cell Lysate
Genistein (100 nM, 1 μM, or 10 μM) was mixed with the cell lysate (the final protein concentration was 500 μg/mL) in 100 mM Tris-HCl buffer (pH 7.4). A solution of 100 μM PAPS was added to start the reaction with a total volume of 300 μL. The mixture was incubated at 37°C for 4 h. The reactions were terminated by the addition of 100 μL of internal standard (10 μM daidzein in acetonitrile). After centrifugation at 16,700×g for 15 min, the supernatant was separated and applied to UPLC-MS/MS for the quantitative analysis.
Measurement of Hydrolytic Enzyme Activities Using Cell Lysate
Tested compound (1 μM G-7-G, G-7-S, or G-4′-S) was mixed with the cell lysates (the final protein concentration was 300 μg/mL) in 100 mM Tris-HCl buffer (pH 7.4) to arrive at a total volume of 300 μL. After incubating at 37°C for 24 h, the reaction was stopped and the sample was prepared by the same method as described above for quantitative analysis by UPLC-MS/MS.
Effect of β-Glucuronidase Inhibitor on the Proliferative Activity of G-7-G to MCF-7 and T47D and on the Hydrolysis of G-7-G Cells were seeded and cultured in 96-well plates in the same way as described above. The cells were incubated with G-7-G (562 nM and 2.25 μM) at 37°C for 3 days with or without a β-glucuronidase inhibitor saccharolactone (0.1, 0.2, and 0.5 mM). Each concentration was assayed in four replicates. All the compounds were dissolved in DMSOethanol (1: 4, v/v), and the final vehicle concentration was 0.1%. Negative controls (no test compounds) received medium containing 0.1% DMSO-ethanol (1: 4, v/v) only. Inhibitor controls were treated with 0.1, 0.2, or 0.5 mM saccharolactone only without G-7-G. Cell proliferation was calculated by the method described above.
In order to evaluate the effect of saccharolactone on the hydrolysis of G-7-G, 60 μL of incubation medium was collected after 3 days incubation. A sample was spiked with 20 μL of internal standard (10 μM daidzein in acetonitrile) and 60 μL of acetonitrile. Then, the mixture was vortexed for 1 min and centrifuged at 16,700×g for 15 min. The supernatant was transferred into another clear centrifuge tube and evaporated to dryness under a stream of nitrogen. The residue was reconstituted in 80 μL of 20% acetonitrile aqueous solution and centrifuged at 16,700×g for 5 min. A 10-μL aliquot of the supernatant was injected into UPLC-MS/ MS system to analyze the remaining amount of G-7-G.
UPLC Analysis
UPLC analysis was carried out first to identify the major metabolites of genistein appearing in incubation media. The UPLC conditions used in the present study were: system, Waters Acquity™ with diode array detector (DAD); column, Acquity UPLC BEH C 18 column (50×2.1 mm ID, 1.7 μm, Waters, Milford, MA, USA); mobile phase A, 2.5 mM ammonium acetate, pH 7. 
UPLC-MS/MS Analysis
The structures of the major metabolites of genistein were identified by mass spectrometry. An API4000 triple quadrupole mass spectrometer (Applied Biosystem/MDS SCIEX, Foster City, CA, USA) was operated in negative ion mode. The main working parameters for the mass spectrometers were set as follows: ionspray voltage, −4.0 kV; ion source temperature, 400°C
; gas1, 40 psi; gas2, 40 psi; curtain gas, 20 psi. The structures of genistein major metabolites were confirmed by MS full scan, MS2 full, and multi-reactions monitoring (MRM) scan modes using synthesized authentic chemical standards.
Because UPLC-DAD analysis was not sensitive enough for the quantitative determination of genistein conjugates formed after incubation, a previously reported UPLC-MS/MS method was modified and applied to analyze the concentrations of genistein and its metabolites in incubation samples (29) . In brief, the quantification was performed using MRM method with the transitions of m/z 269→m/z 133 for genistein, m/z 253→m/z 132 for daidzein (IS), m/z 455→m/z 269 for G-7-G and G-4′-G, and m/z 349→m/z 269 for G-7-S and G-4′-S. The main working parameters were set as follows: ionspray voltage, −4.5 kV; ion source temperature, 500°C; gas1, 30 psi; gas2, 50 psi; curtain gas, 30 psi. Analyte concentrations were determined using the software Analyst 1.5. Genistein and its conjugates were separated by the same UPLC system as described above.
The calibration curves were linear over the concentration ranges of 4.9 nM to 10 μM for genistein, and 2.45 to 1,250 nM for G-7-G, G-7-S, and G-4′-S. The accuracy of the method was well in the range of 85% to 115%. The intra-day and inter-day precision expressed as relative standard deviation was below 15%. Because we did not obtain the reference compound of G-4′-G with enough purity and quantities from the rat's urine, the concentrations of G-4′-G in incubation samples were calculated using the calibration curve of G-7-G in the present study. Doerge et al. and Yang et al. (33, 34) have shown that extinction coefficients of genistein metabolites are similar to that of genistein, indicating that it is feasible to calculate the concentration of G-4′-G by the calibration curve of G-7-G in an LC-UV method. In a preliminary study, the amounts of G-4′-G in the incubation samples collected at 24 h after 10 μM genistein was incubated with MCF-7 cells were analyzed by the UPLC-DAD and UPLC-MS/MS methods separately. The concentrations of G-4′-G were then calculated by the calibration curve of G-7-G in both methods. Compared with the data obtained in the UPLC-DAD analysis, calculation in the UPLC-MS/MS detection did not cause more than 10% relative error. The latter demonstrated that the calculation method for G-4′-G using the calibration curve of G-7-G in the UPLC-MS/MS method was reasonable.
NMR Analysis
NMR spectra were recorded at 300 MHz on a Bruker AMX 300 NMR spectrometer (Bruker, Faellanden, Switzerland). G-7-S and G-4′-S were dissolved in d 6 -DMSO and G-7-G in CD 3 OD. Chemical shifts of 1 H were defined using tetramethylsilane as a reference.
Statistical Analysis
Data are reported as the mean±SD. Independent Student's t test and one-way ANOVA with Tukey-Kramer multiple comparison (post hoc) tests (Minitab. Version 14th) were used to evaluate statistical differences. Differences were considered statistically significant when p values were less than 0.05.
RESULTS
Expression of ERα and β in Breast Cell Lines and the Effect of E2 on the Growth of Breast Cell Lines
As shown in Fig. 2 , ERα was present in MCF-7 and T47D cells but was not detected in MCF-10A cells. ERβ was expressed in all three cell lines. E2, a positive control, significantly stimulated the cell growth of MCF-7 and T47D in the range of 0.1−100 nM, whereas it did not show estrogenic activity in MCF-10A cells due to the lack of ERα (data not shown).
Effects of Genistein, G-7-G, G-7-S, and G-4′-S on the Growth of Breast Cell Lines
Genistein are known to possess biphasic effects on cell growth particularly in ER+ cells, with concentrations between 0.01 and 10 μM stimulating growth of breast tumor cells while concentrations greater than 10 μM inhibit such growth (35) . In the present study, the cell growth of MCF-7 and T47D cells were increased by genistein in a concentration-dependent manner from 25.6 nM to 3.2 μM (p<0.05), but these effects were reversed when genistein concentration achieved 80 μM (Fig. 3a) . On the other hand, the proliferation of MCF-10A was slightly induced at genistein concentrations from 25.6 to 640 nM (p<0.05), but was inhibited by genistein at 80 μM (p<0.05) (Fig. 3a) .
G-7-G caused an approximate 40% proliferative effects on MCF-7 cells at higher concentrations (2.25 and 4.5 μM, p<0.05), whereas the same conjugate greatly increased the growth of T47D cells at much lower concentration (>0.14 nM) (p<0.05) (Fig. 3b) . The growth of MCF-10A cells was weakly stimulated (p<0.05) by G-7-G in the range of 35.2−563 nM (Fig. 3b) . As for genistein sulfates, none of the cell growth of MCF-7, T47D, and MCF-10A appeared as being affected by G-7-S or G-4′-S at any tested concentration (Fig. 3c, d ).
Genistein conjugates (e.g., G-7-G, G-7-S, and G-4′-S) with highly variable effects, which were chemically or biologically synthesized in our lab, were not 100% pure, and they contained about 2% genistein as impurity. Thus, the proliferation of G-7-G, G-7-S, and G-4′-S on MCF-7 and T47D, as shown in Fig. 3b d, were the apparent effects of the tested compounds together with genistein, especially at the levels of 2.25 and 4.5 μM where the concentration of genistein was about 45 nM, which could stimulate the cell growth of MCF-7 and T47D (Fig. 3a) . To clearly reveal their own effects on breast cancer cells, the proliferative percentage of G-7-G, G-7-S, and G-4′-S on MCF-7 and T47D at the concentrations of 2.25 and 4.5 μM were recalculated by subtracting the stimulation effect of genistein from the total apparent effect of conjugates+2% genistein. The percent proliferative results from 2% of genistein was calculated by the rule of three basing on the stimulation effects of genistein in the range of 25.6−128 nM (Fig. 3a) . After the subtraction of the proliferation caused by genistein, G-7-G did not show stimulation effect on the growth of MCF-7 at the concentrations of 2.25 and 4.5 μM, while it still induced the growth of T47D at the level of 4.5 μM (Fig. 3e) . G-7-S and G-4′-S weakly decreased (p>0.05) the growth of T47D at the concentrations of 2.25 and 4.5 μM; and they significantly inhibited the cell growth of MCF-7 at the concentration of 4.5 μM (Fig. 3e) .
Identification of the Major Metabolites of Genistein in Human Breast Cell Lines
To investigate the role of metabolism in the effects of genistein and its phase II conjugates on breast, we first identified the major metabolites of genistein appearing in incubation media by UPLC-DAD method. Four more peaks which have the similar UV absorption profile in addition to genistein were detected in the chromatograms of incubation media collected at 24 h after breast cell lines were treated with 10 μM of genistein (Fig. 4a) . The peaks at 1.30, 1.65, 2.34, and 2.76 min were referred as metabolites M1, M2, M3, and M4, respectively (Fig. 4a) . (Fig. 4c) 
corresponded to the [M-H]
− ion of genistein. The result suggested that M1 and M2 were the mono-glucuronides of genistein. Two monoglucuronides of genistein have been identified in vivo, one is G-7-G and the other is G-4′-G (33,34) . We isolated G-7-G from rat's urine and identified its structure by NMR. The G-7-G standard was used to confirm the structures of M1 and M2. M2 showed the same retention time in UPLC as that of G-7-G standard (Fig. 4b) , thus M2 was identified as G-7-G and M1 was identified as G-4′-G.
Metabolite M3 and M4 had the same [M-H] − ions at m/z 349, which were 80 Daltons higher (characteristic of the addition of sulfuric acid) than that of genistein. The MS2 spectra of M3 and M4 also showed a peak fragment ion at m/ z 269 (Fig. 4c) , indicating that M3 and M4 were the monosulfates of genistein. The identities of M3 and M4 were confirmed by comparing their retention times with those of the reference compounds of G-7-S and G-4′-S which were chemically synthesized in the current study (Fig. 4b) . The result demonstrated that M3 was G-4′-S and M4 was G-7-S.
Metabolism of Genistein in Human Breast Cell Lines
The amounts of genistein metabolites appearing in the incubation media of each cell line were determined by UPLC-MS/MS analysis. As shown in Fig. 5 , the metabolic extent and rate of genistein in different cells were different, which were the least and slowest in MCF-10A cells especially at lower genistein concentrations (100 nM and 1 μM). Genistein was quickly converted to phase II conjugates by MCF-7 and T47D cells. The total amount of conjugates detected in MCF-7 media rapidly reached a plateau at 1 h at the lowest genistein concentration (100 nM, Fig. 5b ) and at 4 h at the middle genistein concentration (1 μM, Fig. 5d ). It kept increasing with time when genistein concentration was increased to 10 μM (Fig. 5f) , which was the same as observed in T47D media at all tested genistein concentrations (Fig. 5b, d, and f) . The total recovery of genistein, calculated as the percent of the sum of genistein and the conjugates detected in media after incubation to the amount of genistein before incubation, was in the range of 85−115%.
Not only the metabolic extent and rate of genistein were different among the cell lines, but also its metabolic pathway. Most of genistein was converted to G-7-G, and some were converted to G-4′-G and G-7-S by MCF-7 cells (Fig. 6) . Compared with other metabolites, G-4′-S was the minor one in this cell line (Fig. 6) . Glucuronidation was the major metabolic pathway of genistein in MCF-7 cells. The ratio of the amount of G-7-G to that of G-4′-G (G-7-G/G-4′-G) in all MCF-7 incubation samples was from 2.7 to 7.8 except in the samples obtained after 24 h incubation at a genistein concentration of 1 μM in which the same ratio was about 20.
Sulfonation appeared to be the predominated metabolic pathway of genistein in T47D cells. G-7-S was the primary metabolite of genistein appearing in T47D media, whose amount was about 15 times (8−20-fold) higher than that of G-4′-S (Fig. 6) . The amounts of glucuronides found in T47D media were below the LLOQ of UPLC-MS/MS method regardless how much genistein was applied in the present.
Genistein was hardly metabolized by MCF-10A, and its metabolic rates were very slow (Fig. 5) . No metabolites were found in MCF-10A media collected after 1 h incubation at all tested genistein concentrations (Fig. 6) . Only a tiny amount of G-7-S was detected in MCF-10A media after 24 h incubation at the lower genistein concentrations (100 nM and 1 μM) (Fig. 6a and b) . When genistein concentration was increased to 10 μM, a small amount of G-7-S was observed in the media after 2 h incubation period, and a trace amount of G-4′-S was detected after 24 h (Fig. 6c) .
Metabolism of G-7-G, G-7-S, and G-4′-S in Human Breast Cell Lines
The metabolism of G-7-G, G-4′-S, and G-7-S in breast cells were investigated by loading a metabolite and then determine the concentration of the aglycone and their metabolites. The result showed that both G-7-S and G-4′-S were slowly metabolized by all three cell lines, and their metabolites amounted to less than 15% after 24 h incubation ( Fig. 7c and e) . Unlike sulfates, the metabolic extent of G-7-G varied with cells in that the metabolism was significantly faster in T47D and MCF-10A cells than in MCF-7 cells after 24 h incubation, although the amounts metabolized appeared to be slow in all the cell types within the 4 h incubation period ( Fig. 7a and b) . After 24 h, the amounts of G-7-G detected in T47D, MCF-10A, and MCF-7 media were 0.12±0.08%, 23.11 ±1.67%, and 80.81±1.04% of the starting concentration, respectively. The total recoveries of the tested conjugates in media were in the range from 85% to 115%, which were measured by the same method of genistein.
The metabolic extent of G-7-G in MCF-7 cells was substantially lower than that of T47D cells, but its metabolic pathway was the same in both of them except that G-4′-G was only found in MCF-7 media. Genistein and G-7-S were the major metabolites, and G-4′-S was the minor one after G-7-G was incubated with MCF-7 and T47D cells for 24 h (Fig. 8a) . The metabolism of G-7-G in MCF-10A cells was dominated by hydrolysis to genistein, which was different from that in MCF-7 and T47D cells (Fig. 8a) .
Four metabolites were identified in MCF-7 media after G-7-S was added to this cell line. They are genistein, G-4′-G, G-7-G, and G-4′-S, among which the amount of G-7-G was obviously higher than the others (Fig. 8b) . Two metabolites of G-7-S, genistein and G-4′-S, were observed in T47D and MCF-10A media. The amount of genistein was significantly higher than the amount of G-4′-S in MCF-10A media after 24 h incubation (Fig. 8b) .
Compared with G-7-S, fewer metabolites were found after G-4′-S was incubated with human breast cell lines. G-4′-G and G-7-G were the two metabolites of G-4′-S detected in MCF-7 media, and the amount of G-7-G was significantly more than the other one (Fig. 8c) . None but G-7-S was found in T47D media after G-4′-S was incubated with T47D cells. No metabolites of G-4′-S were observed in MCF-10A media after 24 h incubation (Fig. 8c) .
Glucuronidation and Sulfation of Genistein in Breast Cell Lysates
Substantial glucuronidation but poor sulfation of genistein was detected in MCF-7 cell lysate, which (c and d) , and 10 μM (e and f) genistein were incubated with MCF-7, T47D, and MCF-10A cells at 37°C for 1, 2, 4, and 24 h (n=3). Left panels show the percentage of genistein remaining in media and right panels show the total amounts of conjugates detected in media indicated that MCF-7 cells possessed high UGT activity but comparatively low SULT activity for genistein. G-7-G was the major metabolite formed in MCF-7 cell lysate. Its formation rate was 10 to 23 times higher than that of G-4′-G (Table I) . Both of the formation rates of G-7-G and G-4′-G were proportional to the substrate concentration (Table I) . On the contrary, genistein was easily metabolized to sulfates by T47D cell lysate without the formation of glucuronides, suggesting T47D cells possessed high SULT activity but comparatively low UGT activity for genistein. The primary metabolite of genistein detected in T47D lysate was G-7-S, and its formation rate was 14 to 20 higher than that of G-4′-S (Table I ). Significant decline was observed in the formation rates of sulfates in T47D cell lysate when genistein concentration was increased from 1 to 10 μM (Table I) . MCF-10A cells had lower UGT and SULT activities since almost no metabolites of genistein were detected in MCF-10A cell lysate except for a trace amount of G-7-S (Table I) .
Hydrolysis of G-7-G, G-7-S, and G-4′-S in Human Breast Cell Lysate
After 24 h incubation, the hydrolysis rates of genistein conjugates in MCF-7, T47D, and MCF-10A cell lysates were 14.1±3.1, 5.1±0.2, and 4.2±0.7 nM 100 μg protein −1 h −1 for G-7-G, respectively; 24.8 ± 0.8, 17.6 ± 0.4, and 24.5 ± 0.9 nM 100 μg protein −1 h −1 for G-7-S, respectively; and 3.3 ±0.8, 6.6±0.4, and 13.1±0.8 nM 100 μg protein −1 h −1 for G-4′-S, respectively. G-7-G was hydrolyzed at a similar rate in T47D and MCF-10A cell lysates, which was about three times slower than that in MCF-7 cell lysate. Compared with G-7-G and G-4′-S, G-7-S was more easily hydrolyzed in each cell lysate. The hydrolytic rate of G-7-S was faster in MCF-7 and MCF-10A cell lysates than in T47D cell lysate. G-4′-S was hydrolyzed the fastest in MCF-10A cell lysate and the slowest in MCF-7 cell lysate.
Effect of β-Glucuronidase Inhibitor on the Proliferative Activity of G-7-G to MCF-7 and T47D and on the Hydrolysis of G-7-G G-7-G appeared to stimulate the growth of MCF-7 and T47D. This stimulation effect may result from G-7-G itself or from genistein which was produced by the hydrolysis of G-7-G intracellularly. In order to evaluate the intrinsic effect of G-7-G, we investigate its proliferation effect on MCF-7 and T47D with and without β-glucuronidase inhibitor, saccharolactone. The concentrations of G-7-G were tested at 562 nM and 2.25 μM which were close to the level of G-7-G in metabolism study. Compared with the negative controls, which only received medium containing 0.1% DMSO- (Fig. 9) . Saccharolactone slightly suppressed (p> 0.05) the cell proliferation of MCF-7 at 0.1 and 0.2 mM, and it Fig. 7 . Amounts of G-7-G, G-7-S, G-4′-S remaining and the total amounts of their metabolites detected in incubation media after G-7-G (a and b), G-7-S (c and d), and G-4′-S (e and f) were incubated with MCF-7, T47D, and MCF-10A cells at 37°C for 1, 2, 4, and 24 h (n=3). The incubation concentrations of G-7-G, G-7-S, and G-4′-S were 1 μM. Left panels show the percentage amounts of G-7-G (a), G-7-S (c), and G-4′-S (e) remaining in media and right panels show the amounts of metabolites of G-7-G (b), G-7-S (d), and G-4′-S (f) detected in media obviously inhibited the growth of MCF-7 at 0.5 mM (Fig. 9a) . This inhibitor also slightly decreased (p>0.05) the growth of T47D in the range of 0.1−0.5 mM (Fig. 9b) . Because saccharolactone seemed to show weak inhibitory activity to the cell growth of MCF-7 and T47D, the proliferation caused by G-7-G was calculated by comparing with the controls which received saccharolactone only to correct the effect of this inhibitor when the cells were treated with G-7-G+ saccharolactone. Our data showed that the proliferative effect of G-7-G on MCF-7 was decreased by 0.1, 0.2, and 0.5 mM saccharolactone from 39.9% to 28.5%, 13.6%, and −11.1% for 562 nM G-7-G, respectively; and from 68.1% to 44.2%, 
GEN genistein, UGT UDP-glucuronosyltransferase, SULTs sulphotransferases 31.2% and 0.2% for 2.25 μM G-7-G, respectively (Fig. 9a) . The proliferative effect of G-7-G on T47D was decreased by 0.1, 0.2, and 0.5 mM saccharolactone from 50.5% to 30.0%, −0.4%, and −4.7% for 562 nM G-7-G, respectively; and from 106.6% to 66.7%, 10.0%, and −19.0% for 2.25 μM G-7-G, respectively (Fig. 9b) . These results indicated that saccharolactone (>0.2 mM) markedly inhibited the stimulation effect of G-7-G on MCF-7 and T47D. G-7-G underwent complex metabolism in MCF-7 and T47D cells (Fig. 8a) , including hydrolysis and reconjugation. Thus, the effect of saccharolactone on the hydrolysis of G-7-G was evaluated by determining the remaining amounts of G-7-G in incubation media after 3 days incubation. Saccharolactone increased the amounts of G-7-G remained in incubation media of MCF-7 and T47D ( Fig. 9c and d) in a concentrationdependent manner.
DISCUSSION
Peterson et al. have investigated the metabolism of genistein in MCF-7, T47D, and normal human mammary epithelial (HME) cells (27, 28) . They reported that genistein was quickly and extensively metabolized in MCF-7 and T47D cells but poorly metabolized in HME cells. In the present study, we also observed extensive metabolism of genistein in MCF-7 and T47D cells and poor metabolism in MCF-10A cells, a non-tumorigenic cell line (Fig. 5) .
Genistein significantly stimulated the cell growth of MCF-7 and T47D in the concentration range from 25.6 nM to 3.2 μM in a concentration-dependent manner (Fig. 3a) . Difference was found in the metabolism of genistein in MCF-7 and T47D cells because of the different UGTs and SULTs activities for genistein in these cells (Table I) , although both of these cells are human ER + . Glucuronidation is the predominant metabolic pathway for genistein in MCF-7 cells, and sulfation is the major one in T47D cells (Fig. 6) . These results indicated that the proliferative effect of genistein on MCF-7, and T47D cells did not relate to its phase II metabolic profile in these cells.
In the current study, G-7-G was the major metabolite of genistein appearing in MCF-7 incubation media. However, G-7-S was identified as the major metabolite of genistein in MCF-7 incubation media by Peterson et al. (27) . The discrepancy may result from the difference in sample preparation. Peterson et al. extracted genistein and its metabolites by SPE method, and 10 mL of the eluate was dried at room temperature with air. The dryness procedure may cause dissociation of G-7-G during sample preparation. Moon et al. detected the metabolites of genistein inside MCF-7 cells and found biochanin A conjugates were the major metabolites besides genistein conjugates (36) . We did not monitor the metabolites of genistein intracellular because the recovery of genistein collected in incubation media (85-115%) was almost complete. In addition, the UPLC-MS/MS analysis performed in this study was not sensitive enough to determine the trace metabolites intracellular because we used a six-well format for our study.
To our knowledge, this is the first report for the investigation of the metabolism of genistein conjugates in breast cells. G-7-G was markedly metabolized by T47D and MCF-10A cells and hardly metabolized by MCF-7 cells after 24 h incubation (Fig. 7a) . To our surprise, G-7-S and G-4′-S underwent a fairly limited metabolism in all three cell lines ( Fig. 7 and 8 ). Enzyme activity study revealed that G-7-S and G-4′-S was hydrolyzed faster than or as fast as G-7-G in T47D and MCF-10A lysates. In addition, the activity of β-glucuronidase in MCF-7 cells was approximately three times higher than in T47D and MCF-10A cells. A lack of a correlation between extent of genistein conjugates metabolism in the whole cells and hydrolytic enzyme activities in cell lysate suggests that the metabolism of genistein conjugates in breast cells were not dependent on the intracellular hydrolytic enzyme activities. Genistein glucuronides and sulfates have poor lipid solubility and carry net negative charges at physiological pH levels, so they must transverse the cell membrane (into the cells) by a carrier-mediated transport before they can react with the hydrolytic enzymes inside the cells. Efflux transporters existed in breast cells, such as MRP2 and BCRP (37, 38) , limit their presence in cells by excreting them rapidly (39) (40) (41) , all of which could lead to weak hydrolytic metabolism. Hence, transporters mediating the influx or efflux of genistein conjugates probably play an important role in the metabolism of genistein conjugates in breast cells, and further studies are underway to define these transporters.
Compared with the aglycone, G-7-G showed weaker stimulation effect on the growth of breast cancer cells. The reduced stimulative activity of G-7-G may result from the intrinsic low proliferative prosperity of G-7-G, or from the partial deglucuronidation of G-7-G. In latter case, the low activity is due to a mixture of inactive monoglucuronide and small amounts of active deglucuronidated aglycone. The metabolism study showed that the added G-7-G was completely metabolized by T47D cells within 24 h, among which approximate 40% was converted to genistein (Figs. 7a and 8a) . Adding G-7-G to T47D cells was equivalent to adding 40% of genistein, hence G-7-G concentration-dependently increased the cell growth from 141 nM to 4.5 μM (Fig. 3b) . On the other hand, due to the low production of genistein from G-7-G in MCF-7 cells, the cell growth of MCF-7 was not increased by G-7-G as obvious as that of T47D, although MCF-7 cells were more sensitive to the stimulating effects of genistein than T47D cells. The proliferation of MCF-7 cells was only increased by G-7-G at higher concentrations (2.25 and 4.5 μM), and this stimulation disappeared after the effect of 2% of genistein presented in G-7-G was deducted (Fig. 3e) . Moreover, saccharolactone, a β-glucuronidase inhibitor, significantly increased the amounts of G-7-G remained in incubation media and obviously decreased the apparent stimulating effect of G-7-G on MCF-7 and T47D (Fig. 9) , suggesting saccharolactone inhibited the hydrolysis of G-7-G in MCF-7 and T47D cells and hence decrease the cell proliferation resulted from the deglucuronidation to genistein. Basing on these data, we speculated that the apparent cell proliferative activity of G-7-G in MCF-7 and T47D was closely related to its deglucuronidation by the cells.
G-7-S and G-4′-S completely abolish the cell proliferative activity of the parent compound (2% were present in the conjugates as impurity) in breast cancer cells, likely because they were slowly metabolized in these cells. It appeared that sulfation is an inactivation/elimination pathway for genistein. However, if the stimulative effects of 2% of genistein coexisted with G-7-S and G-4′-S was taken into consideration, genistein sulfates at a level above 2.25 μM appeared to have quantifiable inhibitory effect on the cell growth (Fig. 3e) . A number of strategies to increase blood concentration of free isoflavones have been proposed by changing soy food/supplements formula or increasing dosage (15, (42) (43) (44) (45) (46) . However, these goals were hard to be realized because of the extensive first-pass metabolism and saturated absorption (16, (47) (48) (49) . If genistein sulfates could inhibit the cell growth of breast cancer cells, increasing blood concentration of isoflavone sulfates would be a viable approach to improve the anticancer effect of isoflavones.
In conclusion, we have shown that genistein's stimulative activity in breast cancer cells (MCF-7 and T47D) were not correlated to its metabolic pathway of conjugation. We have shown for the first time that G-7-G also has stimulative effect on the growth of certain breast cancer cells, as long as these cells could deglucuronidate G-7-G to form the aglycone genistein. In contrast, G-7-S and G-4′-S did not undergo significant metabolism in breast cells and could show mild growth inhibitory effects in these cells. Taken together, the breast cancer preventive activities of isoflavones may be better promoted by the increase in production of genistein sulfates than genistein itself.
